Rain Therapeutics Inc

NASDAQ:RAIN   3:59:53 PM EDT
16.71
-0.75 (-4.30%)
Products, Regulatory

Rain Therapeutics Initiates Phase 3 Mantra Clinical Trial Of Milademetan For De-Differentiated Liposarcoma And Provides Patient Update From Prior Clinical Program

Published: 07/20/2021 12:29 GMT
Rain Therapeutics Inc (RAIN) - Rain Therapeutics Initiates Phase 3 Mantra Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update From Prior Clinical Program.
Rain Therapeutics Inc - As of July 1, Three Wd/dd Lps Patients Received Therapy With Milademetan Monotherapy for Greater Than 51 Months.
Rain Therapeutics Inc - Two of the Three Patients Continue to Receive Therapy With Durations Now at 51 and 57 Months Without Disease Progression.
Rain Therapeutics Inc - Additional Patient Received Therapy for Greater Than 59 Months Before Discontinuation in Q2 of 2021.